The first study was conducted by Wilhelm and collaborators, where a low-dose of IL-2 in combination with pamidronate was tested, according to two different schedules, in 19 patients with relapsed/refractory low-grade NHL (FL, CLL, mantle cell lymphoma-MCL) and MM (61). The gene discussed is IL2; the disease is mantle cell lymphoma.